MVA can stimulate both the humoral and the cell-mediated immune response and it was indicated in several prime-boost regimes as being highly immunogenic. Learn how an innovative process development platform for MVA is impacting vaccine manufacturing and supporting the drug life cycle from process and analytical development through clinical trials and commercialization.
The demand for viral vector vaccines has skyrocketed in the wake of the pandemic. Ensuring the safety and efficacy of these vaccines is of utmost importance. Learn how implementing NGS technology for adventitious virus testing in viral vector vaccine development and manufacturing is crucial for ensuring safety.
Gene therapies come at a high cost to patients and are not yet widely accessible. There is a growing need for manufacturers to provide innovative solutions to reduce costs while maintaining high product quality and safety. This poster presents investigations to derive an economic and scalable method for purification of AAV.
Manufacturing viral vectors leaves sponsors vulnerable to high costs, delays, and the possibility of failure. Leveraging a CDMO's platform processes accelerates the production of clinical trial materials while avoiding expensive mistakes. Learn how the right partner can help you reduce timelines and increase cost-savings for viral vector production.
With more than 30 years of expertise in commercial filling we have expanded our capacities of eight filling lines by another new high-speed line. With batch sizes of up to 500,000 vials, this line is one of the fastest in the world and can serve up to 100 million vials per year.
We support our clients with an overall package of technical know-how, outstanding manufacturing, scientific expertise, process excellence and innovation to bring their treatments flexible and with speed to market.
